Biocraft cephalexin ITC decision
Executive Summary
International Trade Commission agreed unanimously on Aug. 3 that cephalexin imports from Canada are not causing material injury to the domestic generic cephalexin manufacturers. However, in June, the Commerce Department imposed a 7.5% weight-averaged dumping margin on all Canadian cephalexin capsules. Biocraft filed a complaint in October 1988 alleging that cephalexin capsules imported from Canada by Lyphomed/Novopharm were being sold in the U.S. at a less than fair value and were materially injuring the industry. Meanwhile, Biocraft filed similar complaints July 12 against companies importing cephalexin capsules from Portugal and Israel. Biocraft and the importing companies Companhia Industrial Productora de Antibiotics (CIPAN) and Teva Pharmaceuticals appeared before the commission on Aug. 4.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.